Por favor, use este identificador para citar o enlazar este ítem:
http://hdl.handle.net/10201/68724
Twittear
Registro completo de metadatos
Campo DC | Valor | Lengua/Idioma |
---|---|---|
dc.contributor.author | Kameyama, Hiroki | - |
dc.contributor.author | Kudoh, Shinji | - |
dc.contributor.author | Udaka, Naoko | - |
dc.contributor.author | Kagayama, Motoko | - |
dc.contributor.author | Hassan, Wael | - |
dc.contributor.author | Hasegawa, Kohki | - |
dc.contributor.author | Niimori-Kita, Kanako Niimori-Kita | - |
dc.contributor.author | Ito, Takaaki | - |
dc.date.accessioned | 2019-03-29T11:50:40Z | - |
dc.date.available | 2019-03-29T11:50:40Z | - |
dc.date.issued | 2014 | - |
dc.identifier.citation | Histology and Histopathology, vol. 29, nº 5, (2014) | es |
dc.identifier.issn | 1699-5848 | - |
dc.identifier.issn | 0213-3911 | - |
dc.identifier.uri | http://hdl.handle.net/10201/68724 | - |
dc.description.abstract | Adult male mice were continuously treated with bromodeoxyuridine (BrdU) for 1, 2, or 4 weeks by an osmotic pump. To detect BrdU-label-retaining cells (LRCs), putative progenitor/stem cells, other animals were continuously treated with BrdU for 2 weeks, and were then kept without any treatments for 2, 6, or 18 months. The lungs were fixed with 4% paraformaldehyde, and were paraffin-embedded. We observed terminal bronchioles with BrdU immunostaining alone or with BrdU immunostaining accompanying immunostaining for Clara cell secretory protein (CCSP), forkhead box protein J1 (FoxJ1), or calcitonin gene-related peptide (CGRP). The average incidences of BrdU-incorporated cells in the terminal bronchioles after 1, 2, and 4 weeks of continuous BrdU infusion were 6.2%, 11.9%, and 23.1%, respectively. Most BrdU-incorporated cells in these periods were CCSP-immunoreactive (91.7%, 91.3%, and 88.2%, respectively), which means progenitor function of Clara cells. FoxJ1-immunoreactive BrdU-incorporated cells were fewer (5.4%, 3.0%, 2.7%, respectively). The average incidences of BrdU-LRCs in the terminal bronchioles after 2, 6, and 18 months were 7.2%, 4.3, and 2.7%, respectively. Most BrdU-LRCs were CCSP-immunoreactive (91.0%, 92.7%, and 89.6%, respectively), and FoxJ1- immunoreactive BrdU-LRCs were fewer (6.0%, 5.7%, and 2.1%, respectively). CGRP-positive BrdUincorporated cells were occasional. CGRP-positive BrdU-LRCs were detected in 17.6% of neuroepithelial bodies (NEBs) at 2 months, but disappeared at 6 months. BrdU-positive stem cell candidates, which locate at the brochiolo-alveolar duct junction or cover NEB, were few throughout this study. In conclusion, in the lungs treated only with BrdU, CCSP-immunoreactive cells are important to maintain homeostasis in the terminal bronchiolar epithelium. | es |
dc.format | application/pdf | es |
dc.format.extent | 10 | es |
dc.language | eng | es |
dc.publisher | F. Hernández y Juan F. Madrid. Universidad de Murcia: Departamento de Biología Celular e Histología | es |
dc.rights | info:eu-repo/semantics/openAccess | es |
dc.subject | BrdU-label-retaining cell | es |
dc.subject | Lung | es |
dc.subject | Clara cell secretory protein | es |
dc.subject.other | CDU::6 - Ciencias aplicadas::61 - Medicina | es |
dc.title | Bromodeoxyuridine (BrdU)-label-retaining cells in mouse terminal bronchioles | es |
dc.type | info:eu-repo/semantics/article | es |
Aparece en las colecciones: | Vol.29, nº 5 (2014) |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
Kameyama-29-659-668-2014.pdf | 10,35 MB | Adobe PDF | Visualizar/Abrir |
Este ítem está sujeto a una licencia Creative Commons Licencia Creative Commons